# Synergistic interactions of melatonin and glucocorticoids in alleviating allergic airway inflammation

**Authors:** Zhe Zhang, Jipeng Wang, Ting Ma, Xiuqin Zhang, Guilian Chen, Baolan Wang

PMC · DOI: 10.3389/fmed.2026.1738965 · 2026-02-25

## TL;DR

This study shows that combining melatonin with glucocorticoids may improve asthma treatment by reducing inflammation and regulating sleep patterns.

## Contribution

The study demonstrates a novel synergistic therapeutic strategy combining melatonin and glucocorticoids for allergic asthma.

## Key findings

- Melatonin correlates with improved asthma control and sleep quality in clinical studies.
- Animal experiments show melatonin reduces inflammation and stabilizes circadian genes.
- Combining melatonin with glucocorticoids significantly enhances anti-inflammatory effects.

## Abstract

This study investigates the synergistic effects of melatonin and glucocorticoids in the management of asthma and allergic airway inflammation. While glucocorticoids are the cornerstone of asthma treatment, melatonin’s anti-inflammatory properties, potentially mediated through circadian rhythm regulation, may enhance their therapeutic efficacy.

A case–control clinical study was conducted to assess asthma control scores, biochemical markers, exhaled nitric oxide (FeNO), and sleep quality. Additionally, an animal model was utilized to evaluate the effects of melatonin and dexamethasone combination therapy on airway inflammation and circadian rhythm gene expression.

The clinical study found significant correlations between asthma control scores, melatonin and PSQI sleep quality, suggesting that melatonin play crucial roles in asthma control. In parallel, animal experiments revealed that melatonin reduced allergic airway inflammation and stabilized circadian rhythm gene expression. Furthermore, the combination of melatonin with glucocorticoids exhibited a significantly enhanced effect in reducing allergic airway inflammation.

Melatonin, when combined with corticosteroids, may represent a promising therapeutic strategy for allergic asthma, potentially improving asthma control through modulation of inflammation and circadian rhythm regulation. Further studies are needed to fully elucidate the mechanisms underlying this synergy and to evaluate the long-term therapeutic benefits.

Infographic summarizing a study on melatonin and glucocorticoids in allergic airway inflammation, featuring a clinical case-control study and animal experiments. Two main conclusions highlight melatonin's and dexamethasone's synergistic effects and significant correlations with asthma outcomes.

## Linked entities

- **Chemicals:** melatonin (PubChem CID 896), dexamethasone (PubChem CID 5743)
- **Diseases:** asthma (MONDO:0004979)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** allergic (MESH:D004342), asthma (MESH:D001249), airway inflammation (MESH:D007249)
- **Chemicals:** dexamethasone (MESH:D003907), Melatonin (MESH:D008550), nitric oxide (MESH:D009569)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12977073/full.md

---
Source: https://tomesphere.com/paper/PMC12977073